UroGen Pharma Ltd.

3 in Phase 3

Quick facts

Phase 3 pipeline

UGN-102 · Oncology
UGN-102 is a mitomycin C-based intravesical therapy that delivers chemotherapy directly to the bladder urothelium to treat non-muscle invasive bladder cancer.
UGN-103 · Oncology
UGN-103 is a synthetic, small molecule that targets the urothelial cancer cells.
UGN-104 · Oncology
UGN-104 is a synthetic, small molecule that acts as a prodrug, which is converted into its active metabolite in the bladder.

Phase 2 pipeline

Mitomycin for pyelocalyceal solution

Phase 1 pipeline

UGN-301

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: